Table 6.
Hybrid nanogels/hydrogels in preclinical and clinical phase.
| Phase | Hybrid Nanogel/Hydrogel | Application | References |
|---|---|---|---|
| Preclinical | Cholesterol-bearing pullulan (CHP)-W9-peptide | Bone loss disorder | [458] |
| Acryloyl group-modified cholesterol-bearing pullulan and pentaerythritol tetra (mercaptoethyl) polyoxyethylene | Tissue engineering | [159] | |
| Pullulan-g-poly(l-lactide) copolymers | Anticancer drug delivery carrier | [150] | |
| Acrylate group-modified cholesterol-bearing pullulan nanogel (CHPANG) with thiol group-modified poly (ethylene glycol) | Protein delivery | [157] | |
| Clinical | CHP | Vaccines | [459,460,461,462] |
| BioAquacareTM—a novel soft hydrogel based on the poly(ethylene glycol)–soyprotein conjugates | Wound dressing material assessed in partial- and full-thickness wounds in pigs | [463] |